Patient and public involvement in randomised clinical trials: a mixed-methods study of a clinical trials unit to identify good practice, barriers and facilitators.

Cross-sectional survey Patient involvement Public involvement Qualitative research Randomised trials Trial oversight User involvement

Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
23 Oct 2021
Historique:
received: 30 03 2021
accepted: 08 10 2021
entrez: 24 10 2021
pubmed: 25 10 2021
medline: 27 10 2021
Statut: epublish

Résumé

While patient and public involvement (PPI) in clinical trials is beneficial and mandated by some funders, formal guidance on how to implement PPI is limited and challenges have been reported. We aimed to investigate how PPI is approached within a UK Clinical Trials Unit (CTU)'s portfolio of randomised controlled trials, perceived barriers to/facilitators of its successful implementation, and perspectives on the CTU's role in PPI. A mixed-methods study design, involving (1) an online survey of 26 trial managers (TMs) and (2) Interviews with Trial Management Group members and public contributors from 8 case-study trials. Quantitative survey data were summarised using descriptive statistics and interview transcripts analysed thematically. Two public contributors advised throughout and are co-authors. (1) 21 TMs completed the survey; (2) 19 in-depth interviews were conducted with public contributors (n=8), TMs (n=5), chief investigators (n=3), PPI coordinators (n=2) and a researcher. 15/21 TMs surveyed reported that a public contributor was on the trial team, and 5 used another PPI method. 12/21 TMs reported that public contributors were paid (range £10-50/h). 5 TMs reported that training was provided for public contributors and few staff members had received any formal PPI training. The most commonly reported tasks undertaken by public contributors were the review of participant-facing materials/study documents and advising on recruitment/retention strategies. Public contributors wanted and valued feedback on changes made due to their input, but it was not always provided. Barriers to successful PPI included recruitment challenges, group dynamics, maintaining professional boundaries, negative attitudes to PPI amongst some researchers, a lack of continuity of trial staff, and the academic environment. Successful PPI required early and explicit planning, sharing of power and ownership of the trial with public contributors, building and maintaining relationships, and joint understanding and clarity about expectations/roles. CTUs have an important role to play in supporting recruitment, signposting and coordinating PPI. While highly valuable, PPI in trials is currently variable. PPI representatives are recruited informally, may not be provided with any training and are paid inconsistently across trials. Study findings can help optimise PPI in trials and ensure researchers and public contributors are adequately supported.

Sections du résumé

BACKGROUND BACKGROUND
While patient and public involvement (PPI) in clinical trials is beneficial and mandated by some funders, formal guidance on how to implement PPI is limited and challenges have been reported. We aimed to investigate how PPI is approached within a UK Clinical Trials Unit (CTU)'s portfolio of randomised controlled trials, perceived barriers to/facilitators of its successful implementation, and perspectives on the CTU's role in PPI.
METHODS METHODS
A mixed-methods study design, involving (1) an online survey of 26 trial managers (TMs) and (2) Interviews with Trial Management Group members and public contributors from 8 case-study trials. Quantitative survey data were summarised using descriptive statistics and interview transcripts analysed thematically. Two public contributors advised throughout and are co-authors.
RESULTS RESULTS
(1) 21 TMs completed the survey; (2) 19 in-depth interviews were conducted with public contributors (n=8), TMs (n=5), chief investigators (n=3), PPI coordinators (n=2) and a researcher. 15/21 TMs surveyed reported that a public contributor was on the trial team, and 5 used another PPI method. 12/21 TMs reported that public contributors were paid (range £10-50/h). 5 TMs reported that training was provided for public contributors and few staff members had received any formal PPI training. The most commonly reported tasks undertaken by public contributors were the review of participant-facing materials/study documents and advising on recruitment/retention strategies. Public contributors wanted and valued feedback on changes made due to their input, but it was not always provided. Barriers to successful PPI included recruitment challenges, group dynamics, maintaining professional boundaries, negative attitudes to PPI amongst some researchers, a lack of continuity of trial staff, and the academic environment. Successful PPI required early and explicit planning, sharing of power and ownership of the trial with public contributors, building and maintaining relationships, and joint understanding and clarity about expectations/roles. CTUs have an important role to play in supporting recruitment, signposting and coordinating PPI.
CONCLUSIONS CONCLUSIONS
While highly valuable, PPI in trials is currently variable. PPI representatives are recruited informally, may not be provided with any training and are paid inconsistently across trials. Study findings can help optimise PPI in trials and ensure researchers and public contributors are adequately supported.

Identifiants

pubmed: 34688304
doi: 10.1186/s13063-021-05701-y
pii: 10.1186/s13063-021-05701-y
pmc: PMC8542312
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

735

Subventions

Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : CTU support funding

Informations de copyright

© 2021. The Author(s).

Références

Trials. 2020 Jun 18;21(1):543
pubmed: 32552907
Res Involv Engagem. 2018 May 14;4:15
pubmed: 29785283
Soc Sci Med. 2013 Mar;80:24-30
pubmed: 23415588
Health Expect. 2017 Jun;20(3):519-528
pubmed: 27338242
Res Involv Engagem. 2019 Apr 1;5:15
pubmed: 30984414
Res Involv Engagem. 2021 Jun 14;7(1):41
pubmed: 34127074
Patient. 2014;7(4):387-95
pubmed: 25034612
Sociol Health Illn. 2020 May;42(4):809-824
pubmed: 32072657
Health Expect. 2017 Dec;20(6):1401-1410
pubmed: 28618076
Lancet. 2014 Jan 11;383(9912):176-85
pubmed: 24411646
Trials. 2019 Feb 11;20(1):119
pubmed: 30744684
Health Expect. 2011 Dec;14(4):439-48
pubmed: 21176014
Res Involv Engagem. 2016 Apr 27;2:15
pubmed: 29062516
J Eval Clin Pract. 2018 Feb;24(1):240-253
pubmed: 29076631
Nurse Res. 2006 Jul 1;13(4):84
pubmed: 27702218
Sociol Health Illn. 2018 Mar;40(3):463-477
pubmed: 29280538
Trials. 2015 Apr 27;16:190
pubmed: 25928689
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Health Policy. 2004 Aug;69(2):229-38
pubmed: 15212869
PLoS One. 2015 Jun 08;10(6):e0128817
pubmed: 26053063
J Health Serv Res Policy. 2008 Apr;13(2):92-8
pubmed: 18416914
Trials. 2016 Jul 29;17:376
pubmed: 27473060
Health Expect. 2009 Jun;12(2):209-20
pubmed: 19392833
Health Expect. 2021 Aug;24(4):1378-1390
pubmed: 34153165
Br J Psychiatry. 2013 Nov;203(5):381-6
pubmed: 24029538
J Med Ethics. 2013 Mar;39(3):186-7
pubmed: 23288267
BMJ. 2018 Nov 28;363:k4738
pubmed: 30487232
Qual Health Res. 2016 Nov;26(13):1753-1760
pubmed: 26613970
BMJ Open. 2014 Dec 04;4(12):e006400
pubmed: 25475243

Auteurs

Lucy Ellen Selman (LE)

Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK. lucy.selman@bristol.ac.uk.

Clare Clement (C)

Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Margaret Douglas (M)

Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Keith Douglas (K)

Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Jodi Taylor (J)

Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Chris Metcalfe (C)

Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

J Athene Lane (JA)

Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Jeremy Horwood (J)

Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH